Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women

Diagnostic Pathology

Jean-Christophe Noel¹  Philippe Simon¹  Fanny Preat¹ 

[1] Department of Senology, Erasme University Hospital-ULB, Route de Lennik 808, B-1070 Bruxelles, Belgium

关键词: Immunohistochemistry;    Luminal B;    Luminal A;    Molecular classification;    Breast carcinoma;    European;    Arab;   

Others  :  803218
DOI  :  10.1186/1746-1596-9-26

 received in 2013-11-14, accepted in 2013-12-21,  发布年份 2014

【 摘 要 】

Background

There is a dearth of information on the clinicopathological differences, including the molecular subtypes, of breast carcinomas from immigrant Arab women in Europe. Therefore, the aim of our study was to examine and compare these features in immigrant Arab/Moroccan patients with those of European women.

Methods

Included in this study were 441 cases of breast cancer: 91 Arab/Moroccan women and 350 European women. Age, size, grade, node involvement, and immunohistochemical profile (classification into the following subtypes: luminal A, luminal B, HER2 +/ER -, and triple negative) were analyzed.

Results

The average age of breast cancer presentation in Arab women is almost a decade earlier than in European women (49 versus 60 years old; p = 0.00001). Arab patients also had a higher average tumor size (25 mm versus 19 mm; p =0,008) and more grade 3 and less grade 1 tumors (p = 0.02). It should be noted, however, that this variability in the size and grade do not appear statistically significant when compared in Arab and European patients under 50 years old. In contrast, independent of age, the immunohistochemical subtypes were different between the two populations, with a greater number of luminal B subtype and fewer luminal A subtype (p <0.02) in Arab patients.

Conclusions

Arab patients with breast carcinoma have different clinicopathological features from European patients, mainly the age of cancer presentation. Their immunohistochemical profile is also different, with more luminal B and less luminal A subtypes, suggesting that there are not only clinicopathological differences but also disparities in the expression profiling in these women.

Virtual slide

The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2104813621113288 webcite.

【 授权许可】

   
2014 Preat et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
• [2]McPherson K, Steel CM, Dixon JM: Breast cancer: epidemiology, risk factors and genetics. BMJ 2000, 321:624-628.
• [3]Bernstein L, Teal CR, Joselyn S, Wilson J: Ethnicity-related variation in breast cancer risk factors. Cancer 2003, 97:222-229.
• [4]Chouchane L, Boussen H, Satry K: Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol 2013, 14:417-424.
• [5]Teebi AS, Teebi SA: Genetic diversity among the Arabs. Community Genet 2005, 8:21-26.
• [6]El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, Mesbahi O, Amarti A: Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. Diagn Pathol 2012, 7:170. BioMed Central Full Text
• [7]Lakhani SR, Ellis IO, Schnitt SJ, Hoon Tan P, van de Vijver MJ (Eds): WHO classification of tumours of the breast Lyon, France: IARC Press; 2012.
• [8]Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osbome CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep F, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2074-2795.
• [9]Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes C, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Viale G, Zujewski JA, Hayes DF: Assessment of Ki-67 in breast cancer: recommendations from the international KI67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664.
• [10]Schrohl AS, Pedersen HC, Jensen SS, Nielsen S, Brünner N: Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 2011, 59:975-983.
• [11]Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett J, Bilous M, Fitzgibbons P, Hanna W, Jenkins R, Mangu P, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2013, 31:3997-4013.
• [12]Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC: The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States 1999–2004. Cancer Epidemiol Biomarkers Prev 2009, 18:1763-1769.
• [13]El Saghir NS, Khalil MK, Eid T, El Kinge AR, Charafeddine M, Geara F, Seould M, Shamseddine AL: Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 2007, 5:225-233.
• [14]Boulos S, Gadallah M, Neguib S, Essam E, Youssef A, Costa A, Mittra I, Miller AB: Breast screening in the emerging world: high prevalence of breast cancer in Cairo. Breast 2005, 14:340-346.
• [15]Bujassoum SM, Gehani AA: Epidemiology of breast cancer in Qatar 1999–2002. Qatar Med J 2004, 13:43-45.
• [16]El-Zaemey S, Nagi N, Fritschi L, Heyworth J: Breast cancer among Yemeni women using the National Oncology Centre Registry 2004–2010. Cancer Epidemiol 2012, 36:249-253.
• [17]Azaiza F, Cohen M: Health beliefs and rates of breast cancer screening among Arab women. J Womens Health 2006, 15:520-530.
• [18]Mellon S, Gauthier J, Cichon M, Hammad A, Simon MS: Knowledge, attitude and beliefs of Arab-American women regarding inherited cancer risk. J Genet Couns 2013, 22:268-276.
• [19]Kawar LN: Barriers to breast cancer screening participation among Jordanian and Palestinian American women. Eur J Oncol Nurs 2012, 1:88-94.
• [20]Missaoui N, Jaidene L, Abdelkrim SB, Abdelkader A, Beizig N, Yaacoub LB, Yaacoubi MT, Hmissa S: Breast cancer in Tunisia: clinical and pathological findings. Asian Pac J Cancer Prev 2011, 12:169-172.
• [21]Al-Kuraya K, Schraml P, Skeik S, Amr S, Torhost J, Tapia C, Novotny H, Spichtin H, Maurer R, Mislacher M, Simon R, Sauter G: Predominance of high grade pathway in breast cancer development of Middle East women? Mod Pathol 2005, 18:891-895.
• [22]Cakir A, Gonul I, Uluoglu O: A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn Pathol 2012, 7:145. BioMed Central Full Text
• [23]Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hartie T, Eisen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Eystein Lonning P: Gene expression patterns of breast carcinoma distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
• [24]Goldhirsch A, Wood W, Coates AS, Gelber R, Thurslimann B, Senn H: Strategies for subtypes-dealing with diversity of breast cancer: highlights of the St Gallen International expert consensus on primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747.
• [25]Chalabi N, Bernard-Gallon DJ, Bignon Y: Comparative clinical and transcriptomal profiles of breast cancer between French and South Mediterranean patients show minor bit significative biological differences. Cancer Genomics Proteomics 2008, 5:253-261.